Bookmark and Share
BioAssay: AID 451

GR-EFC Redistribution

The glucocorticoid receptor (GR) is a cytoplasmic receptor that belongs to the nuclear receptor family of ligand-dependent transcription factors. Upon glucocorticoid binding to its receptor, the glucocorticoid-GR complex translocates into the nucleus, where it binds as a dimer to specific DNA sequences (glucocorticoid response elements), enhancing or suppressing transcription of a wide variety of more ..
_
   
 Tested Compounds
 Tested Compounds
All(7884)
 
 
Active(38)
 
 
Inactive(7762)
 
 
Inconclusive(101)
 
 
 Tested Substances
 Tested Substances
All(8728)
 
 
Active(40)
 
 
Inactive(8587)
 
 
Inconclusive(101)
 
 
 Related BioAssays
 Related BioAssays
AID: 451
Data Source: NCGC (grefc)
BioAssay Type: Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Screening Center Network
BioAssay Version:
Deposit Date: 2006-07-21
Modify Date: 2006-11-17

Data Table ( Complete ):           View Active Data    View All Data
Target
BioActive Compounds: 38
Description:
NIH Molecular Libraries Screening Centers Network [MLSCN]
NIH Chemical Genomics Center [NCGC]

NCGC Assay Overview:
The glucocorticoid receptor (GR) is a cytoplasmic receptor that belongs to the nuclear receptor family of ligand-dependent transcription factors. Upon glucocorticoid binding to its receptor, the glucocorticoid-GR complex translocates into the nucleus, where it binds as a dimer to specific DNA sequences (glucocorticoid response elements), enhancing or suppressing transcription of a wide variety of glucocorticoid-responsive genes. In addition to their important roles in normal physiology and metabolism, glucocorticoids are administered exogenously as treatments for a wide variety of allergic, autoimmune, and neoplastic conditions. Identification of compounds that modulate aspects of GR signalling would be useful in dissecting glucocorticoid response pathways as well as developing GR modulators with more targeted clinical effects.

Traditionally, GR modulators have been identified using receptor binding or direct transactivation assays. However, assays for glucocorticoid-dependent nuclear translocation can also be used to screen for compounds affecting GR signaling.
Immunocytochemical staining has been used to assay for GR translocation, but is not suitable for high throughout screening due to the multiple reagent addition and wash steps required. Recently, a novel cell-based GR assay in Enzyme Fragment Complementation (EFC) format was developed by DiscoveRx (Fremont, CA). The assay uses EFC of b-galactosidase (b-gal) as an indicator of GR-translocation in engineered CHO-K1 biosensor cells. The enzyme acceptor (EA) fragment of b-gal resides in the nucleus , as designed through the use of a proprietary set of sequence additions and modifications. The small peptide enzyme donor (ED) fragment of b-gal is fused directly to the C-terminus of GR, and is localized in the cytoplasm is the absence of receptor signaling. Upon binding to a GR ligand, the complex translocates to the nucleus, where intact enzyme activity is restored by complementation and b-gal activity is detected. We optimized this GR-EFC assay in homogenous 1536-well plate assay format for high throughput screening.
Protocol
NCGC Assay Protocol Summary:
CHO-K1 cells stably expressing NLS-enzyme acceptor fragment (EA) of b-gal and GR-enzyme donor (ED) fragment of b-gal were maintained in F12 medium (Invitrogen, Carlsbad, CA) at 37 Celsius degrees under a humidified atmosphere containing 5% CO2 and 95% air. The medium contained 10% FBS, 2 mM L-glutamine, 50 U/ml penicillin 50 ug/ml streptomycin, and 250 ug/ml hygromycin and 500 ug/ml G418 (Invitrogen).
GR-translocation was measured beta-gal enzyme activity using the PathHunter Detection Kit containing cell membrane permeablizing reagent and beta-gal substrate (DiscoveRx, Fremont, CA). All compounds were screened as titrations from 0.6 nM to 46 uM final concentration. The assay was performed in 1536-well format as follows:
5 uL cell suspension (1,000 cells)/well
23 nL compound
Incubation at 37 Celsius degrees for two hours
1.25 uL 1X detection buffer from the kit supplied by DiscoveRx
Incubation at room temperature for one hour
Read plate in luminescence mode in ViewLux plate reader (PerkinElmer)
Keywords: NIH Roadmap, MLSCN, MLI, MLSMR, GR-EFC, GREFC, qHTS, NCGC
Comment
References:
Fung, et al. "Homogeneous Cell-Based Assay to Measure Nuclear Translocation Using b-Galactosidase Enzyme Fragment Complementation" ASSAY Drug Devel.Technol. 2006, 4(3), 263-272
Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive
2. Within each curve class, compounds are ranked by potency
Categorized Comment - additional comments and annotations
From PubChem:
Assay Cell Type: CHO-K1
Result Definitions
Show more
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1Activity DirectionIndicates direction of activity: inactive, decreasing, increasing.String
2Activity QualifierIndicates if AC50 is "=" to value or if it is infinite activity (i.e, inactive), ">".String
3Qualified AC50Qualified AC50; can be an IC50 or EC50.Float
4Log of AC50Log of AC50.Float
5Hill CoefficientHill slope of fitted curve.Float
6Curve R2R^2 fit value of curve. Closer to 1.0 equates to better Hill equation fit.Float
7Data TypeNCGC designation for data stage: 'qHTS', 'qHTS Verification', 'Secondary Profiling'String
8Compound QCNCGC comment on compound QC: 'DPI QC', 'NCGC Purified'String
9Data Analysis QCNCGC comment on confidence of data: 'Curve Verfied', etcString
10NCGC CommentAnnotation/notes on a particular compound's data: e.g, 'cytotoxic', 'fluorescent artifact'String
11Curve Fit ModelCurve fitting model used.String
12Hill S0S0 of Hill EquationFloat
13Hill SinfSinf of Hill EquationFloat
14Hill dSdS of Hill EquationFloat
15Log AC50 Std ErrorStandard error for Log AC50.Float
16Excluded PointsIndividual points excluded from curve fitting.String
17Number of PointsNumber of valid points used for fitting.Integer
18Activity at 0.59nM% Activity at given concentration.Float%
19Activity at 1.319nM% Activity at given concentration.Float%
20Activity at 2.95nM% Activity at given concentration.Float%
21Activity at 6.597nM% Activity at given concentration.Float%
22Activity at 14.751nM% Activity at given concentration.Float%
23Activity at 0.033uM% Activity at given concentration.Float%
24Activity at 0.074uM% Activity at given concentration.Float%
25Activity at 0.165uM% Activity at given concentration.Float%
26Activity at 0.369uM% Activity at given concentration.Float%
27Activity at 0.824uM% Activity at given concentration.Float%
28Activity at 1.844uM% Activity at given concentration.Float%
29Activity at 4.122uM% Activity at given concentration.Float%
30Activity at 9.217uM% Activity at given concentration.Float%
31Activity at 20.61uM% Activity at given concentration.Float%
32Activity at 0.046mM% Activity at given concentration.Float%
33Compound TypeNCGC designation for compound stage: 'qHTS ECL (Exploratory)', 'NIHSMR (MLSCN)', 'Compound Followup', 'Compound Verification', 'Probe Optimization'String

Data Table (Concise)
Data Table ( Complete ):     View Active Data    View All Data
PageFrom: